Jackson Financial Valuation
Is JXN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of JXN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: JXN ($98.54) is trading below our estimate of fair value ($677.34)
Significantly Below Fair Value: JXN is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JXN?
Key metric: As JXN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is JXN's PS Ratio? | |
|---|---|
| PS Ratio | 1.8x |
| Sales | US$4.00b |
| Market Cap | US$7.35b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.6x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does JXN's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.7x | ||
VOYA Voya Financial | 1x | 3.3% | US$7.7b |
EQH Equitable Holdings | 1.4x | 14.2% | US$14.6b |
CRBG Corebridge Financial | 1.1x | 12.2% | US$17.3b |
ALRS Alerus Financial | 3.3x | 22.6% | US$549.8m |
JXN Jackson Financial | 1.8x | 13.6% | US$7.3b |
Price-To-Sales vs Peers: JXN is expensive based on its Price-To-Sales Ratio (1.8x) compared to the peer average (1.7x).
Price to Sales Ratio vs Industry
How does JXN's PS Ratio compare vs other companies in the US Diversified Financial Industry?
Price-To-Sales vs Industry: JXN is good value based on its Price-To-Sales Ratio (1.8x) compared to the US Diversified Financial industry average (2.7x).
Price to Sales Ratio vs Fair Ratio
What is JXN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.8x |
| Fair PS Ratio | 2.2x |
Price-To-Sales vs Fair Ratio: JXN is good value based on its Price-To-Sales Ratio (1.8x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$98.54 | US$100.40 +1.9% | 9.6% | US$117.00 | US$88.00 | n/a | 5 |
| Nov ’25 | US$98.32 | US$91.20 -7.2% | 13.1% | US$111.00 | US$74.00 | n/a | 5 |
| Oct ’25 | US$90.25 | US$86.40 -4.3% | 14.3% | US$109.00 | US$74.00 | n/a | 5 |
| Sep ’25 | US$89.97 | US$79.75 -11.4% | 7.8% | US$89.00 | US$74.00 | n/a | 4 |
| Aug ’25 | US$84.88 | US$79.50 -6.3% | 4.5% | US$84.00 | US$74.00 | n/a | 4 |
| Jul ’25 | US$74.99 | US$76.25 +1.7% | 6.4% | US$82.00 | US$70.00 | n/a | 4 |
| Jun ’25 | US$76.01 | US$74.75 -1.7% | 10.4% | US$82.00 | US$62.00 | n/a | 4 |
| May ’25 | US$69.10 | US$65.50 -5.2% | 11.7% | US$75.00 | US$55.00 | n/a | 4 |
| Apr ’25 | US$66.15 | US$57.50 -13.1% | 10.8% | US$68.00 | US$52.00 | n/a | 4 |
| Mar ’25 | US$56.62 | US$57.50 +1.6% | 10.8% | US$68.00 | US$52.00 | n/a | 4 |
| Feb ’25 | US$49.65 | US$51.00 +2.7% | 5.9% | US$55.00 | US$47.00 | n/a | 5 |
| Jan ’25 | US$51.20 | US$44.40 -13.3% | 13.9% | US$55.00 | US$38.00 | n/a | 5 |
| Dec ’24 | US$48.40 | US$43.40 -10.3% | 10.6% | US$50.00 | US$38.00 | n/a | 5 |
| Nov ’24 | US$37.33 | US$39.20 +5.0% | 10.1% | US$46.00 | US$34.00 | US$98.32 | 5 |
| Oct ’24 | US$38.22 | US$38.60 +1.0% | 10.3% | US$46.00 | US$34.00 | US$90.25 | 5 |
| Sep ’24 | US$37.90 | US$37.40 -1.3% | 5.2% | US$40.00 | US$34.00 | US$89.97 | 5 |
| Aug ’24 | US$32.66 | US$37.80 +15.7% | 4.6% | US$40.00 | US$35.00 | US$84.88 | 5 |
| Jul ’24 | US$30.61 | US$37.60 +22.8% | 4.3% | US$40.00 | US$35.00 | US$74.99 | 5 |
| Jun ’24 | US$28.22 | US$38.20 +35.4% | 6.1% | US$42.00 | US$35.00 | US$76.01 | 5 |
| May ’24 | US$35.48 | US$41.60 +17.2% | 9.1% | US$48.00 | US$37.00 | US$69.10 | 5 |
| Apr ’24 | US$37.41 | US$41.20 +10.1% | 9.9% | US$48.00 | US$36.00 | US$66.15 | 5 |
| Mar ’24 | US$42.53 | US$42.60 +0.2% | 15.5% | US$55.00 | US$36.00 | US$56.62 | 5 |
| Feb ’24 | US$45.86 | US$39.80 -13.2% | 8.5% | US$46.00 | US$36.00 | US$49.65 | 5 |
| Jan ’24 | US$34.79 | US$38.40 +10.4% | 11.0% | US$46.00 | US$34.00 | US$51.20 | 5 |
| Dec ’23 | US$37.03 | US$38.40 +3.7% | 11.0% | US$46.00 | US$34.00 | US$48.40 | 5 |
| Nov ’23 | US$37.70 | US$36.00 -4.5% | 8.4% | US$42.00 | US$34.00 | US$37.33 | 5 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
VEF
SEK 2.2b
A venture capital firm specializing in early venture, emerging growth and growth capital investments.
VEFF.F
SEK 0.20
7D
0%
1Y
n/a
Federal Home Loan Mortgage
US$10.4b
Operates in the secondary mortgage market in the United States.
FMCC
US$2.92
7D
0%
1Y
358.8%
ORIX
JP¥3.8t
Provides diversified financial services in Japan, the United States, Asia, Europe, Australasia, and the Middle East.
IX
JP¥106.82
7D
-0.9%
1Y
17.5%